Drug intelligence / Profile preview

Qiangji

Development stage: Preclinical
Lead developer: Southern Medical University
Administration: Oral

Overview

Qiangji is a Traditional Chinese Medicine (TCM) drug being investigated for the treatment of ankylosing spondylitis. It is available in formulations such as granules and pills. Clinical trials are exploring its efficacy and safety in addressing TCM patterns like Gan-shen deficiency and Moist Heat Arthralgia Spasm Syndrome, which are associated with ankylosing spondylitis.

Other names: 强脊颗粒Qiangji Granule强脊丸Qiangji Pill

Beyond the preview

Go deeper on Qiangji.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qiangji.

Explore the full profile